cardiovascular outcomes with glp-1 receptor agonists in type 2 diabetes
Published 7 years ago • 1.7K plays • Length 7:17Download video MP4
Download video MP3
Similar videos
-
9:24
glp-1 agonists in t2d: cardiovascular outcomes data
-
7:11
glp-1 agonists: cv outcomes data in type 2 diabetes
-
4:47
glp-1 receptor agonists and cardiovascular benefit
-
2:38
glp-1 receptor agonists: initial cardiovascular evidence
-
3:38
the use of glp-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients
-
16:41
zooming in on cardiovascular risk control with glucagon-like peptide-1 receptor agonists in diabetes
-
13:54
using glp1 receptor agonists to treat cardiac patients with diabetes
-
19:05
professor miles fisher - the role of glp-1 – clinical trial evidence & future prospects.
-
14:53
fundamentals of sglt2i's and glp-1ra's for cv risk
-
2:56
glp-1 receptor agonists in cardiometabolic syndrome
-
6:11
benefits of sglt2 inhibitors and glp-1 receptor agonists
-
44:36
“weighing in” on glp-1 receptor agonists for people with hiv
-
4:59
using glp-1 agonists in patients with t2d and cvd
-
4:14
optimizing cardiovascular, renal prognosis in diabetes with glp-1, sglt2 combination
-
1:29:07
optimizing cardiovascular outcomes in type 2 diabetes: beyond a1c goals
-
1:02:44
exploring the science and practice of glp-1 receptor agonists
-
8:49
mechanisms of action of glp-1 agonists in t2d
-
5:22
understanding the role of glp-1 medicines in managing type 2 diabetes
-
53:29
efl033 - glp-1 receptor agonists and sglt2 inhibitors in type 1 diabetes